KRAS and lung carcinoma: Lack of sufficient tissue for molecular diagnosis [90], tumor heterogeneity [91], different failure rates of tumor genotyping methods used in routine clinical settings for the detection of EGFR, ALK, and KRAS [30], and associated risks and costs are some of the limitations that make liquid biopsy an appealing future surrogate of tissue biopsy in lung cancer management.